| Literature DB >> 18577993 |
I C De Backer1, G Vreugdenhil, M R Nijziel, A D Kester, E van Breda, G Schep.
Abstract
The short-term beneficial effects of physical rehabilitation programmes after cancer treatment have been described. However, little is known regarding the long-term effects. The purpose of this study was to investigate the long-term effects of high-intensity resistance training compared with traditional recovery. A total of 68 cancer survivors who completed an 18-week resistance training programme were followed for 1 year. During the 1-year follow-up, 19 patients dropped out (14 due to recurrence of cancer). The remaining 49 patients of the intervention group were compared with a group of 22 patients treated with chemotherapy in the same period but not participating in any rehabilitation programme. Outcome measures were muscle strength, cardiopulmonary function, fatigue, and health-related quality of life. One year after completion of the rehabilitation programme, the outcome measures in the intervention group were still at the same level as immediately after rehabilitation. Muscle strength at 1 year was significantly higher in patients who completed the resistance training programme than in the comparison group. High-intensity resistance training has persistent effects on muscle strength, cardiopulmonary function, quality of life, and fatigue. Rehabilitation programmes for patients treated with chemotherapy with a curative intention should include high-intensity resistance training in their programme.Entities:
Mesh:
Year: 2008 PMID: 18577993 PMCID: PMC2453017 DOI: 10.1038/sj.bjc.6604433
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Flow chart of the study.
Patient characteristics of the intervention and comparison groups
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
|
| ||||
| Male | 9 | 18 | 4 | 18 |
| Female | 40 | 82 | 18 | 82 |
|
| ||||
| Breast | 32 | 65 | 14 | 64 |
| Ovarian | 3 | 6 | 0 | 0 |
| HL | 4 | 8 | 2 | 9 |
| NHL | 3 | 6 | 3 | 14 |
| Colorectal | 5 | 10 | 3 | 14 |
| Testis | 2 | 4 | 0 | 0 |
|
| ||||
| Chemotherapy | 49 | 100 | 22 | 100 |
| +Radiotherapy | 3 | 6 | 0 | 0 |
| +Surgery | 14 | 29 | 4 | 18 |
| +Radiotherapy+surgery | 28 | 57 | 17 | 77 |
|
| ||||
| AC, breast | 14 | 29 | 9 | 41 |
| CMF, breast | 7 | 14 | 3 | 14 |
| FEC, breast | 11 | 22 | 2 | 9 |
| Carboplatin–paclitaxel, ovarian | 3 | 6 | 0 | 0 |
| ABVD/EBVP/BEACOPP, HL | 4 | 8 | 2 | 9 |
| CHOP/CVP, NHL | 3 | 6 | 3 | 14 |
| 5-FU leucovorin, colorectal | 5 | 10 | 3 | 14 |
| BEP, testis | 2 | 4 | 0 | 0 |
|
|
|
|
| |
|
| ||||
| Mean | 48 | 8 | 51 | 11 |
|
| ||||
| Height (cm) | 170 | 7 | 173 |
|
| Weight (kg) | 78 | 11 | 77 | 14 |
|
| ||||
| Weeks between last chemotherapy and test week 68 | 96 | 26 | 169 | 26 |
ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine; AC=adriamycin, cyclophosphamide; BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BEP=bleomycin, etoposide, cisplatin; CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone; CMF=cyclophosphamide, methotrexate, fluorouracil; CVP=cyclophosphamide, vincristine, prednisone; EBVP=epirubicin, bleomycin, vincristine, prednisone; FEC=fluorouracil, epirubicin, cyclophosphamide; HL=Hodgkin's lymphoma; NHL=non-Hodgkin's lymphoma.
Effects of training on muscle strength, cardiopulmonary function, fatigue, and quality of life on different time points
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||
| Vertical row | 0.48 (0.16) | 0.69 (0.20) | 0.68 (0.20) | 0.46 (0.11) |
| Leg press | 1.96 (0.51) | 2.79 (0.62) | 2.89 (0.74) | 2.20 (0.51) |
| Bench press | 0.30 (0.11) | 0.46 (0.15) | 0.45 (0.15) | 0.30 (0.11) |
| Pull over | 0.12 (0.05) | 0.25 (0.08) | 0.26 (0.10) | 0.13 (0.06) |
| Lunge | 0.20 (0.09) | 0.42 (0.17) | 0.46 (0.16) | 0.21 (0.10) |
| Abdominal crunch | 0.39 (0.14) | 0.60 (0.17) | 0.64 (0.18) | 0.46 (0.13) |
|
| ||||
| Peak oxygen consumption (ml min−1 kg−1) | 25.7 (6.3) | 28.9 (6.7) | 29.3 (8.4) | 27.8 (5.6) |
| Peak power output (W kg−1) | 2.0 (0.6) | 2.3 (0.7) | 2.5 (0.8) | 2.2 (0.6) |
| Peak heart rate (beats per min) | 167 (17) | 172 (14) | 168 (20) | 165 (18) |
| Ventilatory threshold (ml min−1 kg−1) | 19.2 (4.7) | 22.3 (5.7) | 23.5 (7.1) | 22.2 (4.9) |
|
| ||||
| General fatigue | 13.1 (4.5) | 9.2 (4.1) | 9.9 (4.4) | 10.6 (4.4) |
| Reduced activity | 11.8 (4.4) | 8.1 (3.4) | 8.2 (3.8) | 8.8 (4.3) |
| Mental fatigue | 10.0 (4.4) | 8.8 (3.8) | 8.4 (4.0) | 7.9 (4.2) |
| Physical fatigue | 13.7 (4.1) | 8.1 (3.5)b | 9.2 (4.0) | 9.9 (4.8) |
| Reduced motivation | 8.7 (3.1) | 7.7 (2.8) | 7.8 (3.5) | 8.4 (4.1) |
|
| ||||
| Physical functioning | 72.4 (19.2) | 84.2 (19.0) | 85.5 (18.5) | 81.8 (18.4) |
| Role functioning | 60.3 (24.0) | 79.5 (21.1) | 79.4 (22.5) | 83.3 (20.6) |
| Emotional functioning | 75.6 (20.2) | 85.7 (18.8) | 84.1 (18.4) | 81.3 (20.7) |
| Cognitive functioning | 76.5 (24.4) | 83.8 (21.5) | 85.6 (17.3) | 82.6 (19.3) |
| Social functioning | 68.4 (29.3) | 82.5 (21.6) | 82.3 (24.2) | 84.1 (20.8) |
| Fatigue | 43.6 (23.4) | 22.0 (18.8) | 24.8 (22.0) | 29.8 (21.3) |
HRQOL=health-related quality of life; MFI=multidimensional fatigue index; 1-RM=one-repetition maximum.
All data are means (s.d.).
Significant difference, P<0.01, baseline and post-rehabilitation (repeated measure analyses).
Significant difference, P<0.01, baseline and post-rehabilitation (paired t-tests).
Significant difference, P<0.01, baseline and week 68 (repeated measure analyses).
Significant difference, P<0.01, baseline and week 68 (paired t-tests).
Significant difference, P<0.01, the intervention and comparison groups (independent sample t-tests).
Figure 2Muscle strength from start of rehabilitation up to 12 months after completing rehabilitation.